Cinacalcet reduces serum calcium concentrations in patients with intractable primary hyperparathyroidism (Q35545384)

8 August 2017

title

Cinacalcet reduces serum calcium concentrations in patients with intractable primary hyperparathyroidism (English)

1 reference

primary hyperparathyroidism

8 August 2017

1 reference

1 reference

4

John Bilezikian

1 reference

8 August 2017

3

Dolores Shoback

1 reference

8 August 2017

2

Philippe Chanson

1 reference

8 August 2017

Claudio Marcocci

1

1 reference

8 August 2017

Laureano Fernandez-Cruz

5

1 reference

8 August 2017

Jacques Orgiazzi

6

1 reference

8 August 2017

Christoph Henzen

7

1 reference

8 August 2017

Sunfa Cheng

8

1 reference

8 August 2017

Lulu Ren Sterling

9

1 reference

8 August 2017

John Lu

10

1 reference

8 August 2017

Munro Peacock

11

1 reference

8 August 2017

language of work or name

English

0 references

publication date

26 May 2009

1 reference

The Journal of Clinical Endocrinology and Metabolism

8 August 2017

published in

1 reference

8 August 2017

volume

94

1 reference

8 August 2017

issue

8

1 reference

8 August 2017

page(s)

2766-2772

1 reference

The OPTIMA study: assessing a new cinacalcet (Sensipar/Mimpara) treatment algorithm for secondary hyperparathyroidism

8 August 2017

cites work

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3214593

Cinacalcet hydrochloride reduces the serum calcium concentration in inoperable parathyroid carcinoma

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3214593

Effect of parathyroidectomy on quality of life and neuropsychological symptoms in primary hyperparathyroidism

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3214593

Cinacalcet hydrochloride maintains long-term normocalcemia in patients with primary hyperparathyroidism

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3214593

Alendronate in primary hyperparathyroidism: a double-blind, randomized, placebo-controlled trial

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3214593

Pharmacodynamics of the Type II Calcimimetic Compound Cinacalcet HCl

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3214593

A practical approach to hypercalcemia

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3214593

Recurrent or persistent hyperparathyroidism

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3214593

Clinical spectrum of primary hyperparathyroidism: Evolution with changes in medical practice and technology

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3214593

Effect of cinacalcet hydrochloride, a new calcimimetic agent, on the pharmacokinetics of dextromethorphan: in vitro and clinical studies.

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3214593

Prospective evaluation of quality of life (SF-36v2) and nonspecific symptoms before and after cure of primary hyperparathyroidism (1-year follow-up).

26 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3214593

Cinacalcet HCl, an oral calcimimetic agent for the treatment of secondary hyperparathyroidism in hemodialysis and peritoneal dialysis: a randomized, double-blind, multicenter study

26 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3214593

Cinacalcet for secondary hyperparathyroidism in patients receiving hemodialysis

26 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3214593

Recurrence of hyperparathyroidism; a long-term follow-up after surgery for primary hyperparathyroidism

26 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3214593

Raloxifene lowers serum calcium and markers of bone turnover in postmenopausal women with primary hyperparathyroidism

26 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3214593

Surgical treatment of hyperparathyroidism improves health-related quality of life

26 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3214593

The concept of clinically meaningful difference in health-related quality-of-life research. How meaningful is it?

26 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3214593

Raloxifene reverses bone loss in postmenopausal women with mild asymptomatic primary hyperparathyroidism

26 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3214593

Randomized trial of parathyroidectomy in mild asymptomatic primary hyperparathyroidism: patient description and effects on the SF-36 health survey.

26 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3214593

Overview of the SF-36 Health Survey and the International Quality of Life Assessment (IQOLA) Project.

26 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3214593

The evolution of parathyroidectomy failures

26 September 2018

1 reference

12 December 2020

Quality of life and patient satisfaction after reoperation for primary hyperparathyroidism: analysis of long-term results

1 reference

12 December 2020

Salmon calcitonin in hypercalcemia

1 reference

12 December 2020

Effect of hormone replacement therapy on bone mineral density in postmenopausal women with mild primary hyperparathyroidism. A randomized, controlled trial

1 reference

12 December 2020

Parathyroid function and bone metabolic markers in primary and secondary hyperparathyroidism

1 reference

12 December 2020

Changes in bone mass and serum markers of bone metabolism after parathyroidectomy

1 reference

12 December 2020

Health status improvement after surgical correction of primary hyperparathyroidism in patients with high and low preoperative calcium levels

1 reference

12 December 2020

The American Association of Clinical Endocrinologists and the American Association of Endocrine Surgeons position statement on the diagnosis and management of primary hyperparathyroidism

1 reference

12 December 2020

Identifiers

DOI

10.1210/JC.2008-2640

1 reference

release_tyso2hkp6rasfji7vhlopcdaqa

8 August 2017

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/tyso2hkp6rasfji7vhlopcdaqa

24 November 2022

mapped directly with Wikidata item

PMC publication ID

3214593

1 reference

8 August 2017

1 reference